After Considering Patients’ Well-being, Rubraca Continues to Benefit Women with Recurrent Ovarian Cancer, Analysis Shows
News
Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients’ perceptions about their health, disease symptoms, and treatment toxicity, a retrospective analysis of ... Read more